Publications

2007

Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, Vlahou A, Papadaki HA, Antsaklis A, Anagnou NP.Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells.Stem Cells Dev. 2007 Dec;16(6):931-52.

Pyrovolaki K, Mavroudi I, Papadantonakis N, Velegraki M, Ximeri M, Kalpadakis C, Gvazava G, Klaus M, Eliopoulos GD, Papadaki HA. Transforming growth factor-beta1 affects interleukin-10 production in the bone marrow of patients with chronic idiopathic neutropenia. Eur J Haematol. 2007 Oct 23; [Epub ahead of print]

Galanopoulos AG, Symeonidis A, Kourakli A, Papadaki EA, Tsaftaridis P, Terpos E, Aktipi A, Roussou P, Protopappa M, Pappaioannou M, Zikos P, Speletas M, Parcharidou A, Laoutaris N, Anagnostopoulos NI, Meletis J, Pangalis GA, Zoumbos N, Viniou N; Hellenic MDS Study Group. Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group.Eur J Haematol. 2007 Jan;78(1):89-90.

 
Froudarakis ME, Papadaki HA, Klimathianaki M, Damianaki A, Pougounias M, Kotsianidis I, Astoul P. Thoracoscopic talc poudrage decreases T-lymphocytes in the peripheral blood. Respir Med. 2007 Jun;101(6):1212-7. Epub 2006 Dec 19.
  

2008

Papadaki HA and Pontikoglou C. Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia. Exp Rev Hematol 2008;1:217-229

Ziakas PD, Papadaki HA, Psyllaki M, Voulgarelis M. Anti-thrombopoietin antibodies supress megakaryocytic colony formation in vitro in patients with systemic lupus erythematosus.  Ann Rheum Dis.2008 Nov;67(11):1643-4.

Kastrinaki MC, Andreakou I, Charbord P, Papadaki HA. Isoslation of human bone marrow mesenchymal stem cells using different membrane markers: Comparion of colony/cloning efficiency, differentiation potential, and molecular profile.  Tissue Eng Part C Methods. 2008 Dec;14(4):333-339.

Kastrinaki MC, Sidiropoulos P, Roche S, Ringe J, Lehmann S, Kritikos H, Vlahava VM, Delorme B, Eliopoulos GD, Jorgensen C, Charbord P, Haupl T, Boumpas DT, Papadaki HA. Functional, molecular and proteomic characterization of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis. 2008 Jun;67(6):741-9.

Nakou M, Knowlton N, Frank MB, Bertsias G, Osban J, Sandel CE, Papadaki HA, Raptopoulou A, Sidiropoulos P, Kritikos I, Tassiulas I, Centola M, Boumpas DT.Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. Arthritis Rheum . 2008 Nov;58(11):3541-9.

Stamatopoulos K, Papadaki T, Pontikoglou C, Athanasiadou I, Stavroyianni N, Bux J, Batsis I, Pyrovolaki K, Paterakis G, Anagnostou D, Anagnostopoulos A, Papadaki HA. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia. 2008 Jan 10; [Epub ahead of print] 


Palmblad J, Papadaki HA. Chronic idiopathic neutropenias and severe congenital neutropenia.Curr Opin Hematol. 2008 Jan;15(1):8-14.   
   

2009

Klaus M, Stavroulaki E, Kastrinaki MC, Fragioudaki P, Giannikou K, Psyallaki M, Pontikoglou CG, Tsoukatou D, Mamalaki C, Papadaki HA. Reserves, functional, immunoregulatory and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2009 Sep 29. [Epub ahead of print]

Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA; on behalf of the Hellenic MDS Study Group.Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndromes associated with chromosome 5q deletion. Haematologica. 2009 Sep 22. [Epub ahead of print]

Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131. Epub 2009 Aug 28. 

Eliopoulos DG, Mavroudi I, Pontikoglou C, Ximeri M, Stavroulaki E, Pyrovolaki K, Velegraki M, Spanoudakis M, Goulielmos G, Papadaki HA. The -509C/T polymorphism of transforming growth factor-beta1 is associated with increased risk for development of chronic idiopathic neutropenia.Eur J Haematol. 2009 Jul 14. [Epub ahead of print]
 

Polioudaki H, Kastrinaki MC, Papadaki HA, Theodoropoulos PA. Microtubule-interacting drugs induce moderate and reversible damage to human bone marrow mesenchymal stem cells. Cell Prolif. 2009 Aug;42(4):434-47. Epub 2009 May 22.

Pyrovolaki K, Mavroudi I, Sidiropoulos P, Eliopoulos AG, Boumpas DT, Papadaki HA. Increased expression of CD40 on bone marrow CD34+ hematopoietic progenitor cells in patients with systemic lupus erythematosus: contribution to Fas-mediated apoptosis.Arthritis Rheum. 2009 Feb;60(2):543-52.
 

Roche S, Delorme B, Oostendorp RA, Barbet R, Caton D, Noel D, Boumediene K, Papadaki HA, Cousin B, Crozet C, Milhavet O, Casteilla L, Hatzfeld J, Jorgensen C, Charbord P, Lehmann S. Comparative proteomic analysis of human mesenchymal and embryonic stem cells: towards the definition of a mesenchymal stem cell proteomic signature. Proteomics. 2009 Jan;9(2):223-32.

Kastrinaki MC, Papadaki HA. Mesenchymal stromal cells in rheumatoid arthritis: biological properties and clinical applications. Curr Stem Cell Res Ther. 2009 Jan;4(1):61-9. Review.

2010

Klaus M, Psaraki A, Mastrodemou S, Pyrovolaki K, Mavroudi I, Kalpadakis C, Papadaki HA. Evaluation of TET2 deletions in myeloid disorders: A fluorescence in situ hybridization analysis of 109 cases. Leuk Res. 2010 Nov 17. [Epub ahead of print]

Stavroulaki E, Kastrinaki MC, Pontikoglou CG, Eliopoulos DG, Damianaki A, Mavroudi I, Pyrovolaki K, Katonis P, Papadaki HA. Mesenchymal stem cells contribute to the abnormal bone marrow microenvironment in patients with chronic idiopathic neutropenia by overproduction of transforming growth factor-β1. Stem Cells Dev. 2010 Nov 3. [Epub ahead of print]

Spanoudakis M, Koutala H, Ximeri M, Pyrovolaki K, Stamatopoulos K, Papadaki HA. T-cell receptor Vβ repertoire analysis in patients with chronic idiopathic neutropenia demonstrates the presence of aberrant T-cell expansions. Clin Immunol. 2010 Dec;137(3):384-95. Epub 2010 Sep 22.

Mavroudi I, Pyrovolaki K, Pavlaki K, Kozana A, Psyllaki M, Kalpadakis C, Pontikoglou C, Papadaki HA. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res. 2010 Aug 3. [Epub ahead of print]

Kastrinaki MC, Pontikoglou C, Klaus M, Stavroulaki E, Pavlaki K, Papadaki HA. Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes.

Curr Stem Cell Res Ther. 2010 Jun 9. [Epub ahead of print]

Pontikoglou C, Papadaki HA. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin. 2010 Jun;34(3):291-304.

2011

Pontikoglou C, Kalpadakis C, Papadaki HA. Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia. Expert Rev Hematol. 2011 Jun;4(3):317-28.

Mavroudi I, Papadaki HA The role of CD40/CD40 ligand interactions in bone marrow granulopoiesis. ScientificWorldJournal. 2011;11:2011-9. Epub 2011 Oct 26.

Mavroudi I, Papadaki V, Pyrovolaki K, Katonis P, Eliopoulos AG, Papadaki HA. The CD40/CD40 ligand interactions exert pleiotropic effects on bone marrow granulopoiesis. J Leukoc Biol. 2011 May;89(5):771-83. Epub 2011 Mar 2.

Klaus M, Psaraki A, Mastrodemou S, Pyrovolaki K, Mavroudi I, Kalpadakis C, Papadaki HA. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases. Leuk Res. 2011 Mar;35(3):413-5. Epub 2010 Nov 18.

Pontikoglou C, Deschaseaux F, Sensebé L, Papadaki HA.Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev. 2011 Jan 20. [Epub ahead of print]

2012

Gemetzi C, Mavroudi I, Koutala H, Velegraki M, Choulaki C, Damianaki A, Pontikoglou C,Papadaki HA. Lymphopenia in patients with chronic idiopathic neutropenia is associated with decreased number of T-lymphocytes containing T-cell receptor excision circles. Eur J Haematol. 2012 Mar;88(3):210-2. Epub 2011 Nov 24.

Velegraki M, Koutala H, Tsatsanis C, Papadaki HA. Increased levels of the high mobility group box 1 protein sustain the inflammatory bone marrow microenvironment in patients with chronic idiopathic neutropenia via activation of toll-like receptor 4. Clin Immunol. 2012 Apr;32(2):312-22. Epub 2011 Nov 30.

Pavlaki KI, Kastrinaki MC, Klontzas M, Velegraki M, Mavroudi I, Papadaki  HA.Abnormal telomere shortening of peripheral blood mononuclear cells and granulocytes in patients with chronic idiopathic neutropenia . Haematologica. 2012 May;97(5):743-50. Epub 2011 Dec 1.

Antoniou KM, Margaritopoulos GA, Proklou A, Karagiannis K, Lasithiotaki I, Soufla G,Kastrinaki MC, Spandidos DA, Papadaki HA, Siafakas NM. Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP. J Inflamm (Lond). 2012 Jul 2;9(1):27.

Mastrodemou S, Vazgiourakis V, Velegraki M, Pavlaki K, Goulielmos GN, Papadaki HA.Clonal patterns of X-chromosome inactivation in peripheral blood cells of female patients with chronic idiopathic neutropenia. Haematologica. 2012 Aug 8. [Epub ahead of print]

Mavroudi I, Papadaki HA. Genetic associations in acquired immune-mediated bone marrow failure syndromes: insights in aplastic anemia and chronic idiopathic neutropenia. Clin Dev Immunol. 2012;2012:123789. Epub 2012 Aug 26.

2013

Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, Kokoris SI, Dimitriadou EM, Dimopoulou MN, Moschogiannis M, Korkolopoulou P, Kyrtsonis MC, Siakantaris MP, Papadaki T, Tsaftaridis P, Plata E, Papadaki HE, Vassilakopoulos TP. Oncologist. 2013;18(2):190-7.

2014

Levidou G, Sachanas S, Pangalis GA, Kalpadakis C, Yiakoumis X, Moschogiannis M, Sepsa A, Lakiotaki E, Milionis V, Kyrtsonis MC, Vassilakopoulos TP, Tsirkinidis P, Kontopidou F, Kokoris S, Siakantaris M, Angelopoulou M, Papadaki HΑ, Kavantzas N, Panayiotidis P, Patsouris E, Korkolopoulou P.Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis,  Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significance. Biomed Res Int. 2014; 2014:251479. doi: 10.1155/2014/251479. Epub 2014 May 5.

Marketou ME, Parthenakis FI, Kalyva A, Pontikoglou C, Maragkoudakis S, Kontaraki JE, Zacharis EA, Chlouverakis G, Patrianakos A, Papadaki HA, Vardas PE.Increased mobilization of mesenchymal stem cells in patients with essential hypertension: the effect of left ventricular hypertrophy. J Clin Hypertens . 2014;16(12):883-8.

Kalpadakis C, Pangalis GA, Sachanas S, Vassilakopoulos TP, Kyriakaki S, Korkolopoulou P, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Kyrtsonis MC, Levidou G, Papadaki HA, Panayiotidis P, Angelopoulou MK. New insights into monoclonal B-cell lymphocytosis. Biomed Res Int. 2014;2014:258917.

Kalpadakis C, Pangalis GA, Vassilakopoulos TP, Kyriakaki S, Yiakoumis X, Sachanas S, Moschogiannis M, Tsirkinidis P, Korkolopoulou P, Papadaki HA, Angelopoulou MK.Clinical aspects of malt lymphomas. Curr Hematol Malig Rep. 2014 Sep;9(3):262-72.

Zeidler C, Grote UA, Nickel A, Brand B, Carlsson G, Cortesão E, Dufour C, Duhem C, Notheis G, Papadaki HA, Tamary H, Tjønnfjord GE, Tucci F, Van Droogenbroeck J, Vermylen C, Voglova J, Xicoy B, Welte K. Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry. Haematologica. 2014 Aug;99(8):1395-402.

Palmblad J, Dufour C, Papadaki HA. How we diagnose neutropenia in the adult and elderly patient. Haematologica. 2014 Jul;99(7):1130-3.

Marketou ME, Kalyva A, Parthenakis FI, Pontikoglou C, Maragkoudakis S, Kontaraki JE, Chlouverakis G, Zacharis EA, Patrianakos A, Papadaki HA, Vardas PE. Circulating endothelial progenitor cells in hypertensive patients with increased arterial stiffness. J Clin Hypertens. 2014 Apr;16(4):295-300.PMID: 24641802

Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E, Kontakis M, Galanopoulos A, Kotsianidis I, Kastrinaki MC, Papadaki HA. Impaired Proliferative Potential of Bone Marrow Mesenchymal Stromal Cells in Patients with Myelodysplastic Syndromes Is Associated with Abnormal WNT Signaling Pathway. Stem Cells Dev. 2014 Jul 15;23(14):1568-81.

Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Vakalopoulou S, Garypidou V, Papaioannou M, Hadjiharissi E, Pappa V, Papadaki HA, Spanoudakis E, Tsatalas K, Kotsianidis I. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. Blood Cancer J. 2014 Feb 28;4:e187.

Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou F, Moschogiannis M, Ximeri M, Tsirkinidis P, Yiakoumis X, Papadaki HA, Vassilakopoulos TP. Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group. Leuk Lymphoma. 2014 2014 Nov;55(11):2640-2.Mar 25.

c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. Leventaki V, Drakos E, Karanikou M, Psatha K, Lin P, Schlette E, Eliopoulos A, Vassilakopoulos TP, Papadaki HA, Patsouris E, Medeiros LJ, Rassidakis GZ. Hum Pathol. 2014 Mar;45(3):565-72.

Kastrinaki MC, Pavlaki K, Batsali AK, Kouvidi E, Mavroudi I, Pontikoglou C, Papadaki HA. Mesenchymal stem cells in immune-mediated bone marrow failure syndromes. Clin Dev Immunol. 2013;2013:265608.

Xochelli A, Kalpadakis C, Gardiner A, Baliakas P, Vassilakopoulos TP, Mould S, Davis Z, Stalika E, Kanellis G, Angelopoulou MK, McIver-Brown N, Ibbotson R, Sachanas S, Korkolopoulou P, Athanasiadou A, Anagnostopoulos A, Papadaki HA, Papadaki T, Stamatopoulos K, Pangalis GA, Oscier D. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood. 2014 Feb 20;123(8):1199-206.

2015

Kyritsi EM, Yiakoumis X, Pangalis GA, Pontikoglou C, Pyrovolaki K, Kalpadakis C, Mavroudi I, Koutala H, Mastrodemou S, Vassilakopoulos TP, Vaiopoulos G, Diamanti-Kandarakis E, Papadaki HA, Angelopoulou MK. High Frequency of Thyroid Disorders in Patients Presenting With Neutropenia to an Outpatient Hematology Clinic STROBE-Compliant Article. Medicine (Baltimore). 2015 Jun;94(23):e886.

Marketou ME, Parthenakis FI, Kalyva A, Pontikoglou C, Maragkoudakis S, Kontaraki JE, Zacharis EA, Patrianakos A, Chlouverakis G, Papadaki HA, Vardas PE. Circulating mesenchymal stem cells in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2015;24(3):149-53.

Chatzinikolaidou M, Rekstyte S, Danilevicius P, Pontikoglou C, Papadaki HΑ, Farsari M, Vamvakaki M. Adhesion and growth of human bone marrow mesenchymal stem cells on precise-geometry 3D organic-inorganic composite scaffolds for bone repair Mater Sci Eng C Mater Biol Appl. 2015;48:301-9.

Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki HΑ, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I, Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia. 2015. doi: 10.1038/leu.2015.120

Sachanas S, Pangalis GA, Kalpadakis C, Levidou G, Yiakoumis X, Moschogiannis M, Kyrtsonis MC, Vassilakopoulos TP, Tsirkinidis P, Siakantaris M, Spiliadi C, Karagianni E, Korkolopoulou P, Rontogianni D, Papadaki H, Panayiotidis P, Angelopoulou M. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. Leuk Lymphoma. 2015 Nov;56:3230-2.

2016

Damianaki A, Stagakis E, Mavroudi I, Spanoudakis M, Koutala H, Papadogiannis F, Kanellou P, Pontikoglou C, Papadaki HA. Minor populations of paroxysmal nocturnal haemoglobinuria type cells in patients with chronic idiopathic neutropenia. Eur J Haematol. 2016 Apr 28. [Epub ahead of print]

Kalpadakis C, Pangalis GA, Sachanas S, Rontogianni D, Korkolopoulou P, Milionis V, Vassilakopoulos TP, Papadaki HA, Angelopoulou MK. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. Leuk Lymphoma. 2016 Apr 15:1-4. [Epub ahead of print]

Kouvidi E, Stratigi A, Batsali A, Mavroudi I, Mastrodemou S, Ximeri M, Papadaki HA, Pontikoglou CG.Cytogenetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion. Leuk Res. 2016 Feb 18;43:24-32.

Palmblad J, Nilsson CC, Höglund P, Papadaki HA. How we diagnose and treat neutropenia in adults. Expert Rev Hematol. 2016 Feb 16:1-9.

Miltiades P, Lamprianidou E, Vassilakopoulos TP, Papageorgiou SG, Galanopoulos AG, Kontos CK, Adamopoulos PG, Nakou E, Vakalopoulou S, Garypidou V, Papaioannou M, Hatjiharissi E, Papadaki HA, Spanoudakis E, Pappa V, Scorilas A, Tsatalas C, Kotsianidis I; Hellenic MDS Study Group. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. Clin Cancer Res. 2015 Dec 23. [Epub ahead of print]

Kalyva A, Marketou ME, Parthenakis FI, Pontikoglou C, Kontaraki JE, Maragkoudakis S, Petousis S, Chlouverakis G, Papadaki HA, Vardas PE. Endothelial progenitor cells as markers of severity in hypertrophic cardiomyopathy. Eur J Heart Fail. 2016 Feb;18(2):179-84.

2017

Mavroudi I, Eliopoulos AG, Pontikoglou C, Pyrovolaki K, Damianaki A, Koutala H, Zervou MI, Ximeri M, Mastrodemou S, Kanellou P, Goulielmos GN, Papadaki HA. Immunoglobulin and B-cell disturbances in patients with chronic idiopathic neutropenia. Clin Immunol. 2017 Oct;183:75-81. doi: 10.1016/j.clim.2017.07.009.

Mastrodemou S, Stalika E, Vardi A, Gemenetzi K, Spanoudakis M, Karypidou M, Mavroudi I, Hadzidimitriou A, Stavropoulos-Giokas C, Papadaki HA, Stamatopoulos K. Cytotoxic T cells in chronic idiopathic neutropenia express restricted antigen receptors. Leuk Lymphoma. 2017 May 23:1-8.doi: 10.1080/10428194.2017.1324154.[Epub ahead of print]

Batsali AK, Pontikoglou C, Koutroulakis D, Pavlaki KI, Damianaki A, Mavroudi I, Alpantaki K, Kouvidi E, Kontakis G, Papadaki HA. Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther. 2017 Apr 26;8(1):102.doi: 10.1186/s13287-017-0555-9.

2018

Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P,Papadaki HA, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. Am J Hematol. 2018 Jul;93(7):895-901.
 

Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-Azacytidine. A retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematol Oncol. 2018 Aug 20. doi: 10.1002/hon.2551. [Epub ahead of print]
 

Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K, Ioannou P, Pontikoglou C, Papadaki HA, Tzardi M, Belle V, Ettiene E, Beauvais A, Samonis G, Kontoyiannis DP, Andreakos E, Bruno VM, Ibrahim AS, Chamilos G. Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat Commun. 2018 Aug 20;9(1):3333.doi: 10.1038/s41467-018-05820-2.
 

Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. Leuk Res. 2018 Aug;71:55-59.
 

Umansky V, Adema GJ, Baran J, Brandau S, Van Ginderachter JA, Hu X, Jablonska J, Mojsilovic S, Papadaki HA, Pico de Coaña Y, Santegoets KCM, Santibanez JF, Serre K, Si Y, Sieminska I, Velegraki M, Fridlender ZG. Interactions among myeloid regulatory cells in cancer. Cancer Immunol Immunother. 2018 Jul 12. doi: 10.1007/s00262-018-2200-6. [Epub ahead of print]
 

Pontikoglou C, Kalyva A, Kalpadakis C, Velegraki M, Bizymi N, Alpantaki K, Kontakis G, Pangalis GA, Papadaki HA. Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells. Leuk Lymphoma. 2018 Jul 3:1-3.
 

Kalpadakis C, Pangalis GA, Sachanas S, Tsirkinidis P, Kontopidou FN, Moschogiannis M, Yiakoumis X, Koulieris E, Dimopoulou MN, Kokkoris SI, Kyrtsonis MC, Siakantaris MP, Tsourouflis G, Korkolopoulou P, Rontogianni D, Tsaftaridis P, Plata E, Papadaki HA, Panagiotidis P, Angelopoulou MK, Vassilakopoulos TP. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018 Aug 9;132(6):666-670. 

Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. Hematol Oncol. 2018 Jun 8. doi: 10.1002/hon.2521. [Epub ahead of print]